Drug Discovery news from FierceBiotech
News
Pozen shares sink on latest Trexima delay
Pozen stock took a painful dive this morning after GlaxoSmithKline announced that their two-in-one migraine drug Trexima would be delayed yet again--this time to satisfy Read more...
Anadys dumps hep B compound in restructuring
Anadys Pharmaceuticals in San Diego is also restructuring to account for a development failure. Out the door go 29 of 88 employees as it halts work on ANA975 for hepatitis B. Toxicology testing on Read more...
Tobira garners $31M to advance HIV drugs
Up-start biotech Tobira Therapeutics, which is developing HIV/AIDS drugs, has raised $31 million in its first round of venture capital. Domain Associates and Frazier Healthcare Ventures led the round Read more...
J&J makes big cuts at Alza and Scios
Two Bay area biotechs, Alza and Scios, are in line for some big layoffs as Johnson & Johnson slims down its pharma Read more...
SurModics paying up to $62M for Brookwood
The Southern Research Institute has sold Brookwood Pharmaceuticals to SurModics for $40 million up front and up to $22 million in milestones. Both SurModics and Brookwood specialize in Read more...
Lilly developing biotech drugs the old-fashioned way
Pharma's biotech strategy is pretty clear: Buy companies or license in drugs and technology to get a leg up in the Read more...
Get more Drug Discovery coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets